Related Experiment Videos
Standard and intermediate risk acute lymphoblastic leukemia in Poland: a report of the Polish Children's
U Radwanska1, D Michalewska, P Kolecki
1University School of Medicine, Poznań, Poland.
Insights
An intensified treatment program for childhood acute lymphoblastic leukemia (ALL) significantly improved event-free survival rates in standard and intermediate risk groups. This study shows a rise in survival from 55% to 73% for children with ALL.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Trials
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Treatment protocols evolve to improve patient outcomes.
- Risk stratification is crucial for tailoring ALL therapy.
Purpose of the Study:
- To evaluate an intensified treatment program for pediatric ALL.
- To compare outcomes in standard risk group (SRG) and intermediate risk group (IRG) patients.
- To assess the impact of intermediate-dose methotrexate on treatment efficacy.
Main Methods:
- Retrospective analysis of 527 children with ALL (SRG and IRG) treated 1987-1991.
- Treatment based on the BFM protocol with intensified therapy.
- Comparison with 513 children treated 1981-1987.
Main Results:
- The 6-year event-free survival increased significantly to 73% in the treated cohort.
- This represents a substantial improvement from the previous survival rate of 55%.
- The intensified BFM protocol demonstrated enhanced efficacy in SRG and IRG ALL patients.
Conclusions:
- Intensified treatment protocols, including intermediate-dose methotrexate, improve survival for pediatric ALL.
- The BFM protocol is effective in enhancing event-free survival for standard and intermediate risk ALL.
- Further research can build upon these findings for optimizing ALL treatment strategies.
Abstract:
A total of 527 children with acute lymphoblastic leukaemia (ALL) from the most frequent risk groups: standard risk group (SRG) and intermediate risk group (IRG) were treated between 1987 and 1991 according to an intensified treatment program (based on the BFM protocol) including the use of an intermediate dose of methotrexate in the IRG. A comparison of the treatment results in this group from 513 children treated between 1981 and 1987 indicates that the chance for a 6 year event-free survival has increased to 73% (previously 55%).